Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.32 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27638750 | 0.82 | NPC1 (0.50) | MAPTLMNANPC1STSGRM4 | |
| SCHEMBL15779430 | 0.80 | MAPT (0.50) | MAPTLMNAALDH1A1PKML3MBTL1 | |
| SCHEMBL16908308 | 0.78 | MAPT (0.38) | MAPTLMNATDO2ALDH1A1PKM | |
| SCHEMBL21877560 | 0.76 | IDH1 (0.35) | NPC1STSKAT6AGRM4RAB9A | |
| SCHEMBL31517576 | 0.76 | KMT2A (0.37) | MAPTALDH1A1PKMNPC1STS | |
| SCHEMBL6733486 | 0.72 | GAA (0.41) | MAPTLMNAALDH1A1PKML3MBTL1 | |
| SCHEMBL221485 | 0.71 | GAA (0.59) | MAPTNPC1GRM4MPORAB9A | |
| SCHEMBL17076791 | 0.71 | GAA (0.31) | MAPTLMNA | |
| SCHEMBL9952472 | 0.69 | MEN1 (0.42) | MAPTLMNAALDH1A1PKMGRM4 | |
| Hydrochloric Acid SCHEMBL18397939 | 0.69 | GAA (0.57) | MAPTNPC1GRM4MPORAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408767-B1 | AMIDE DERIVATIVES AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | LUNDBECK & CO AS H (DK) | 2013-07-10 | — | — | EP | claimed |
| CN-102356079-A | Amide derivatives as neuropeptide y5 receptor ligands | LUNDBECK & CO AS H | 2012-02-15 | — | — | CN | claimed |
| WO-2010108052-A2 | AMIDE DERIVATIVES AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | H. LUNDBECK A/S (DK) | 2010-09-23 | — | — | WO | claimed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| EP-2408767-B1 | AMIDE DERIVATIVES AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | LUNDBECK & CO AS H (DK) | 2013-07-10 | — | — | EP | disclosed |
| CN-102356079-A | Amide derivatives as neuropeptide y5 receptor ligands | LUNDBECK & CO AS H | 2012-02-15 | — | — | CN | disclosed |
| WO-2010108052-A2 | AMIDE DERIVATIVES AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | H. LUNDBECK A/S (DK) | 2010-09-23 | — | — | WO | disclosed |
| US-7157472-B2 | Neuropeptide Y Y5 receptor antagonists | SCHERING CORPORATION (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157472-B2 | Neuropeptide Y Y5 receptor antagonists | SCHERING CORPORATION (US) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | MAPT 470/4885LMNA 3015/4885TDO2 1709/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | MAPT 501/4885LMNA 3243/4885TDO2 971/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | MAPT 470/4885LMNA 3015/4885TDO2 1709/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | MAPT 438/4885LMNA 3115/4885TDO2 1491/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | MAPT 438/4885LMNA 3115/4885TDO2 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.